<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37632035</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Virus Inactivation by Formaldehyde and Common Lysis Buffers.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1693</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v15081693</ELocationID><Abstract><AbstractText>Numerous mammalian viruses are routinely analyzed in clinical diagnostic laboratories around the globe or serve as indispensable model systems in viral research. Potentially infectious viral entities are handled as blood, biopsies, or cell and tissue culture samples. Countless protocols describe methods for virus fixation and inactivation, yet for many, a formal proof of safety and completeness of inactivation remains to be shown. While modern nucleic acid extraction methods work quite effectively, data are largely lacking on possible residual viral infectivity, e.g., when assessed after extended culture times, which maximizes the sensitivity for low levels of residual infectiousness. Therefore, we examined the potency and completeness of inactivation procedures on virus-containing specimens when applying commonly used fixatives like formaldehyde or nucleic acid extraction/lysis buffers. Typical representatives of different virus classes, including RNA and DNA viruses, enveloped and non-enveloped, such as adenovirus, enterovirus, lentivirus, and coronavirus, were used, and the reduction in the in vitro infectiousness was assessed for standard protocols. Overall, a 30-minute incubation with formaldehyde at room temperature effectively inactivated all tested enveloped and non-enveloped viruses. Full inactivation of HIV-1 and ECHO-11 was also achieved with all buffers in the test, whereas for SARS-CoV-2 and AdV-5, only five of the seven lysis buffers were fully effective under the tested conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seeburg</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Molecular Virology, Department Biomedicine, University of Basel, 4009 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urda</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0007-4122-515X</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department Biomedicine, University of Basel, 4009 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otte</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0572-617X</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department Biomedicine, University of Basel, 4009 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lett</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Molecular Virology, Department Biomedicine, University of Basel, 4009 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caimi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Virology, Department Biomedicine, University of Basel, 4009 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mittelholzer</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4353-3555</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department Biomedicine, University of Basel, 4009 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimkait</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4945-6511</Identifier><AffiliationInfo><Affiliation>Molecular Virology, Department Biomedicine, University of Basel, 4009 Basel, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1HG84L3525</RegistryNumber><NameOfSubstance UI="D005557">Formaldehyde</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038301" MajorTopicYN="Y">Virus Inactivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005557" MajorTopicYN="N">Formaldehyde</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biosafety</Keyword><Keyword MajorTopicYN="N">inactivation</Keyword><Keyword MajorTopicYN="N">virus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37632035</ArticleId><ArticleId IdType="pmc">PMC10458352</ArticleId><ArticleId IdType="doi">10.3390/v15081693</ArticleId><ArticleId IdType="pii">v15081693</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Classification of Organisms (Switzerland)  [(accessed on 24 July 2023)].  Available online:  https://www.bafu.admin.ch/bafu/en/home/topics/biotechnology/publications-studies/publications/classification-of-organisms.html.</Citation></Reference><Reference><Citation>Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products.  [(accessed on 24 July 2023)].  Available online:  https://www.who.int/publications/m/item/WHO-TRS924-Annex4.</Citation></Reference><Reference><Citation>ICH Guideline Q5A(R2) on Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin-Scientific Guideline.  [(accessed on 24 July 2023)].  Available online:  https://www.ema.europa.eu/en/ich-guideline-q5ar2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-animal.</Citation></Reference><Reference><Citation>Virus Safety Evaluation of Biotechnological Investigational Medicinal Products-Scientific Guideline.  [(accessed on 24 July 2023)].  Available online:  https://www.ema.europa.eu/en/virus-safety-evaluation-biotechnological-investigational-medicinal-products-scientific-guideline.</Citation></Reference><Reference><Citation>Widera M., Westhaus S., Rabenau H.F., Hoehl S., Bojkova D., Cinatl J., Jr., Ciesek S. Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings. Med. Microbiol. Immunol. 2021;210:235–244. doi: 10.1007/s00430-021-00716-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-021-00716-3</ArticleId><ArticleId IdType="pmc">PMC8245923</ArticleId><ArticleId IdType="pubmed">34196781</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabenau H.F., Cinatl J., Morgenstern B., Bauer G., Preiser W., Doerr H.W. Stability and inactivation of SARS coronavirus. Med. Microbiol. Immunol. 2005;194:1–6. doi: 10.1007/s00430-004-0219-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-004-0219-0</ArticleId><ArticleId IdType="pmc">PMC7086689</ArticleId><ArticleId IdType="pubmed">15118911</ArticleId></ArticleIdList></Reference><Reference><Citation>Elveborg S., Monteil V.M., Mirazimi A. Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes. Pathogens. 2022;11:271. doi: 10.3390/pathogens11020271.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020271</ArticleId><ArticleId IdType="pmc">PMC8879476</ArticleId><ArticleId IdType="pubmed">35215213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Q., Lim J.Y., Xue K., Yew P.Y.M., Owh C., Chee P.L., Loh X.J. Sanitizing agents for virus inactivation and disinfection. View. 2020;1:e16. doi: 10.1002/viw2.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/viw2.16</ArticleId><ArticleId IdType="pmc">PMC7267133</ArticleId><ArticleId IdType="pubmed">34766164</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvi G., De Los Rios P., Vendruscolo M. Effective interactions between chaotropic agents and proteins. Proteins Struct. Funct. Bioinform. 2005;61:492–499. doi: 10.1002/prot.20626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.20626</ArticleId><ArticleId IdType="pubmed">16152629</ArticleId></ArticleIdList></Reference><Reference><Citation>Otte F., Zhang Y., Spagnuolo J., Thielen A., Däumer M., Wiethe C., Stoeckle M., Kusejko K., Klein F., Metzner K.J., et al. Swiss HIV Cohort Study, Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods. Cell Rep. Methods. 2023;3:100485. doi: 10.1016/j.crmeth.2023.100485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crmeth.2023.100485</ArticleId><ArticleId IdType="pmc">PMC10326345</ArticleId><ArticleId IdType="pubmed">37426753</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimkait T., Stauffer F., Lupo E., Sonderegger-Rubli C. Dissecting the mode of action of various HIV-inhibitor classes in a stable cellular system. Arch. Virol. 1998;143:2109–2131. doi: 10.1007/s007050050447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s007050050447</ArticleId><ArticleId IdType="pubmed">9856097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno H., Ikeda H., Takeuchi M., Yoshida T. A simple and rapid reverse transcriptase assay for the detection of retroviruses in cell cultures. Cytotechnology. 1999;29:221–227. doi: 10.1023/A:1008000210125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1008000210125</ArticleId><ArticleId IdType="pmc">PMC3463392</ArticleId><ArticleId IdType="pubmed">19003345</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei C., Yang J., Hu J., Sun X. On the Calculation of TCID(50) for Quantitation of Virus Infectivity. Virol. Sin. 2021;36:141–144. doi: 10.1007/s12250-020-00230-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00230-5</ArticleId><ArticleId IdType="pmc">PMC7973348</ArticleId><ArticleId IdType="pubmed">32458296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo K.A., Jones S.A., Church T.M., Fuschino M.E., George K.S., Lamson D.M., Maffei J., Kramer L.D., Ciota A.T. Unreliable Inactivation of Viruses by Commonly Used Lysis Buffers. Appl. Biosaf. 2017;22:56–59. doi: 10.1177/1535676017703383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535676017703383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>